Trial Profile

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Nov 2024 Status changed from planning to recruiting.
05 Aug 2024 According to a Salubris Biotherapeutics media release, recruitment is expected to commence in Q3 2024.
05 Aug 2024 According to a Salubris Biotherapeutics media release, company announced it has received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of JK06.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com